New Randomized Trial Shows Promising Cognitive Gains in Long COVID Brain Fog Using Home-Based Light Therapy

Vielight Neuro RX Gamma device and irradiation configuration used in the randomized, double-blind, sham-controlled trial. The ...

Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus ...

Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus ...

Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531)

Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m2 or greater –– ...
News-Medical.Net on MSN

Trial finds no benefit of anti-inflammatory therapy in trachomatous trichiasis surgery

John Kempen, MD, MPH, PhD, MHS, Director of Epidemiology for Ophthalmology at Mass Eye and Ear and Harvard Medical School, is ...
Thorax

Online cognitive behaviour therapy for asthma-related anxiety: a randomised controlled trial

Objective Anxiety affects up to one-third of adults with asthma and is linked to poorer disease outcomes and reduced quality ...
ascopubs.org

Laparoscopic Versus Open Hemihepatectomy: The ORANGE II PLUS Multicenter Randomized Controlled Trial

To compare outcomes after laparoscopic versus open major liver resection (hemihepatectomy) mainly for primary or metastatic cancer. The primary outcome measure was time to functional recovery.
BMJ Global Health

School-based behaviour change intervention to reduce ultra-processed food consumption among adolescents: evidence from a cluster-randomised controlled tri…

Background The global surge in ultra-processed food (UPF) consumption is a major public health challenge, particularly among ...
The New England Journal of Medicine

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response relationships with respect to side effects ...